Perry Blackshear, M.D., D.Phil.

Senior Investigator

Signal Transduction Laboratory / Post-Transcriptional Gene Expression Group


F187 Rall Building
111 T W Alexander Dr
Research Triangle Park, NC 27709


Research Topics

The major research focus of my laboratory is on the regulation of gene expression by the post-transcriptional modification of mRNA stability and translation. Gene expression in response to external, including environmental, stimuli, is a dynamic balance between mRNA synthesis and decay, and we focus on the regulation of the mRNA degradation step. Most of our work involves a family of CCCH tandem zinc finger proteins; members of this family are expressed in organisms ranging from yeasts to man, and have been shown to be involved in a variety of physiological processes in yeasts, insects, mammals and amphibians.

We initially cloned the prototype of this family, TTP, in a screen for insulin-induced genes. This protein is an RNA binding protein that contains a central tandem CCCH zinc finger domain. It uses this zinc finger domain to bind to a specific type of AU-rich sequence in its RNA targets, and then promotes RNA decay by stimulating the removal of the polyA tail. This mechanism is thought to obtain in all the family members from man to yeast. The biochemical mechanism of this stimulated deadenylation, and its sites of regulation, is one of our main lines of ongoing research.

The first discovered and physiologically most important TTP target in mice is the mRNA encoding tumor necrosis factor alpha (TNF). We discovered this by knocking out the gene encoding TTP, which resulted in a systemic inflammatory syndrome driven by excess TNF. We eventually showed that TTP bound directly to the 3'-untranslated region of this mRNA, and that this binding led to accelerated decay of the mRNA. Conversely, the absence of TTP led to abnormal slowing of the TNF mRNA decay rate, its abnormal accumulation, and the abnormal accumulation of synthesized TNF protein. This novel mechanism for regulating TNF synthesis and secretion is a potential target for both new drug development, and for discoveries concerning the effects of environmental influences on the innate immune system. Studies are underway in both these areas; specifically, we are screening libraries of chemical compounds for potential drugs that increase TTP biosynthesis in the absence of TNF secretion, and investigating human populations for TTP sequence abnormalities that might predispose them to inflammatory diseases. We are also continuing to work on the identification of other TTP target transcripts and how they relate to the physiology of the intact organism.

We are also studying the other three mammalian TTP family members, and by doing so have determined that they are involved, respectively, in early formation of the umbilical circulation; hematopoietic stem cell development; and placental physiology. In each case, the identities of physiological mRNA targets of these proteins are topics of active investigation.

Finally, to improve our understanding of the fundamental mechanisms this novel method of regulating gene expression, we have extended our studies into other model organisms, including benign and pathogenic yeasts. We are also investigating the mechanisms of regulation of TTP family member proteins using purely in vitro assay systems as well as the tools of structural biology.


Dr. Blackshear obtained his DPhil degree in biochemistry from the University of Oxford in 1974, and his MD from Harvard Medical School in 1977. He did his internship and residency in internal medicine, and fellowship in endocrinology at the Massachusetts General Hospital and Harvard Medical School, and remained there as an Assistant Professor of Medicine. In 1984, he moved to Duke University, where he was an Investigator of the Howard Hughes Medical Institute and, ultimately, Professor of Medicine and of Biochemistry. He moved to the NIEHS as Clinical Director and Senior Investigator in 1997, and became acting Scientific Director in 2007. He is currently a Senior Investigator in the Laboratory of Signal Transduction, NIEHS.

Selected Publications

  1. Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD, Schenkman DI, Gilkeson GS, Broxmeyer HE, Haynes BF, Blackshear PJ. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity. 1996;4(5):445-54.

  2. Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science. 1998;281(5379):1001-5.

  3. Carballo E, Lai WS, Blackshear PJ. Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood. 2000;95(6):1891-9.

  4. Stumpo DJ, Byrd NA, Phillips RS, Ghosh S, Maronpot RR, Castranio T, Meyers EN, Mishina Y, Blackshear PJ. Chorioallantoic fusion defects and embryonic lethality resulting from disruption of Zfp36L1, a gene encoding a CCCH tandem zinc finger protein of the Tristetraprolin family. Mol Cell Biol. 2004;24(14):6445-55.

  5. Stumpo DJ, Broxmeyer HE, Ward T, Cooper S, Hangoc G, Chung YJ, Shelley WC, Richfield EK, Ray MK, Yoder MC, Aplan PD, Blackshear PJ. Targeted disruption of Zfp36l2, encoding a CCCH tandem zinc finger RNA-binding protein, results in defective hematopoiesis. Blood. 2009;114(12):2401-10.

This page was last updated on April 10th, 2013